This site became the new ClinicalTrials.gov on June 19th. Learn more.
Show more
ClinicalTrials.gov Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more...
ClinicalTrials.gov Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more...
ClinicalTrials.gov Menu
Give us feedback

Immunogenicity and Safety of GSK Biologicals' Boostrix Polio Vaccine in 3 and 4-year-old Children

This study has been completed.
Sponsor:
Information provided by (Responsible Party):
GlaxoSmithKline
ClinicalTrials.gov Identifier:
NCT01245049
First received: November 18, 2010
Last updated: April 12, 2017
Last verified: February 2017
November 18, 2010
April 12, 2017
April 1, 2011
March 27, 2012   (Final data collection date for primary outcome measure)
  • Number of Subjects With a Booster Response to Diphtheria (D) and Tetanus (T) Antigens [ Time Frame: At Month 1, one month after the booster vaccination ]
    Booster response was defined as: For initially seronegative subjects [i.e. pre-vaccination concentration below (<) cut-off value of 0.1 international units per milliliter (IU/mL)] antibody concentrations at least four times the assay cut-off [post vaccination concentration greater than or equal to (≥) 0.4 IU/ml]. For initially seropositive subjects (pre-vaccination concentration ≥ 0.1 IU/ml), an increase in antibody concentrations of at least four times the Pre booster vaccination concentration.
  • Anti-pertussis Toxoid (Anti-PT), Anti-filamentous Haemagglutinin (Anti-FHA) and Anti-pertactin (Anti-PRN) Antibody Concentrations [ Time Frame: At Month 1, one month after the booster vaccination ]
    Antibody concentrations were presented as geometric mean concentrations (GMCs), expressed in enzyme-linked immunosorbent assay (ELISA) units per milliliter (EL.U/mL).
  • Anti-Polio Virus Type 1, 2 and 3 Antibody Titers [ Time Frame: At Month 1, one month after the booster vaccination ]
    Antibody titers were presented as geometric mean titers (GMTs).
Immunogenicity with respect to the components of the study vaccines. [ Time Frame: One month after booster vaccination ]
Complete list of historical versions of study NCT01245049 on ClinicalTrials.gov Archive Site
  • Number of Seroprotected Subjects Against Diphteria (D) and Tetanus (T) [ Time Frame: Before (Month 0) and one month after (Month 1) the booster vaccination ]
    A seroprotected subject was defined a subject with anti-D and anti-T antibody concentrations ≥ 0.1 international units per millilitre (IU/mL).
  • Number of Seropositive Subjects for Anti-PT, Anti-FHA and Anti-PRN [ Time Frame: Before (Month 0) and one month after (Month 1) the booster vaccination ]
    A seropositive subject for anti-PT, anti-FHA and anti-PRN was a subject whose antibody concentration was ≥ 5 EL.U/mL.
  • Number of Seroprotected Subjects Against Polio Type 1, 2 and 3 [ Time Frame: Before (Month 0) and one month after (Month 1) the booster vaccination ]
    A seroprotected subject was defined as a subject with anti-polio type 1, 2 and 3 antibody titres ≥ the value of 8.
  • Number of Seropositive Subjects for Anti-measles Antibody [ Time Frame: Before (Month 0) and one month after (Month 1) the booster vaccination ]
    A seropositive subject was defined as a subject with anti-measles antibody titers ≥ 150 mIU/mL.
  • Number of Seropositive Subjects for Anti-mumps Antibody [ Time Frame: Before (Month 0) and one month after (Month 1) the booster vaccination ]
    A seropositive subject was defined as a subject with anti-mumps antibody titers ≥ 231 U/mL.
  • Number of Seropositive Subjects for Anti-rubella Antibody [ Time Frame: Before (Month 0) and one month after (Month 1) the booster vaccination ]
    A seropositive subject was defined as a subject with anti-rubella antibody titers ≥ 4 IU/mL.
  • Anti-D and Anti-T Antibody Concentrations [ Time Frame: Before (Month 0) and one month after (Month 1) the booster vaccination ]
    Antibody concentrations were presented as geometric mean concentrations (GMCs), expressed in IU/mL.
  • Anti-PT, Anti-FHA and Anti-PRN Antibody Concentrations [ Time Frame: At Month 0, before the booster vaccination ]
    Antibody concentrations were presented as geometric mean concentrations (GMCs), expressed in EL.U/mL.
  • Anti-mumps Antibody Concentrations [ Time Frame: Before (Month 0) and one month after (Month 1) the booster vaccination ]
    Antibody concentrations were presented as geometric mean concentrations (GMCs), expressed in U/mL.
  • Anti-measles Antibody Concentrations [ Time Frame: Before (Month 0) and one month after (Month 1) the booster vaccination ]
    Antibody concentrations were presented as geometric mean concentrations (GMCs), expressed in mIU/mL.
  • Anti-rubella Antibody Concentrations [ Time Frame: Before (Month 0) and one month after (Month 1) the booster vaccination ]
    Antibody concentrations were presented as geometric mean concentrations (GMCs), expressed in IU/mL.
  • Anti-Polio Type 1, 2 and 3 Antibody Titers [ Time Frame: At Month 0, before the booster vaccination ]
    Antibody titers were presented as geometric mean titers (GMTs).
  • Number of Subjects With a Booster Response to PT, FHA and PRN Antigens [ Time Frame: At Month 1, one month after the booster vaccination ]
    Booster response was defined as: For initially seronegative subjects (pre-vaccination concentration < 5 EL.U/mL), antibody concentrations at least four times the assay cut-off (post vaccination concentration ≥ 20 EL.U/mL). For initially seropositive subjects (with pre-vaccination concentration ≥ 5 EL.U/mL and < 20 EL.U/mL), an increase in antibody concentrations of at least four times the Pre booster vaccination concentration. For initially seropositive subjects (with pre-vaccination concentration ≥ 20 EL.U/mL), an increase in antibody concentrations of at least two times the Pre booster vaccination concentration.
  • Number of Subjects With Booster Response for Polio Type 1, 2 and 3 Antigens [ Time Frame: At Month 1, one month after the booster vaccination ]
    Booster response defined as: For initially seronegative subjects, antibody titers at least four times the cut-off (post-vaccination titer ≥ 32); For initially seropositive subjects, an increase in antibody titers of at least four times the Pre booster vaccination titer.
  • Number of Seroconverted Subjects for Anti-measles [ Time Frame: Before (Month 0) and one month after (Month 1) the booster vaccination ]
    Seroconversion for anti-measles was defined as the appearance of antibodies after vaccination in subjects who were initially seronegative [with antibody concentrations ≥ 150 milli-international units per millilitre (mIU/mL)].
  • Number of Seroconverted Subjects for Anti-mumps [ Time Frame: Before (Month 0) and one month after (Month 1) the booster vaccination ]
    Seroconversion for anti-mumps was defined as the appearance of antibodies after vaccination in subjects who were initially seronegative [with antibody concentrations ≥ 231 units per millilitre (U/mL)].
  • Number of Subjects With Any Solicited Local Symptoms [ Time Frame: During the 4-day (Days 0-3) follow-up period after booster vaccination ]
    Assessed solicited local symptoms were pain, redness and swelling. Any = occurrence of the symptom regardless of intensity grade.
  • Number of Subjects With Any Solicited General Symptoms [ Time Frame: During the 4-day (Days 0-3) follow-up period after booster vaccination ]
    Assessed solicited general symptoms were drowsiness, irritability, loss of appetite and temperature [defined as axillary temperature equal to or above 37.5 degrees Celsius (°C)]. Any = occurrence of the symptom regardless of intensity grade.
  • Number of Subjects With Any Unsolicited Adverse Events (AEs) [ Time Frame: During the 31-day (Days 0-30) follow-up period after booster vaccination ]
    An unsolicited AE covers any untoward medical occurrence in a clinical investigation subject temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product and reported in addition to those solicited during the clinical study and any solicited symptom with onset outside the specified period of follow-up for solicited symptoms. Any was defined as the occurrence of any unsolicited AE regardless of intensity grade or relation to vaccination.
  • Number of Subjects With Serious Adverse Events (SAEs) [ Time Frame: During the entire study period (From Day 0 to Month 1) ]
    Serious adverse events (SAEs) assessed include medical occurrences that result in death, are life threatening, require hospitalization or prolongation of hospitalization or result in disability/incapacity.
  • Immunogenicity with respect to the components of the study vaccines. [ Time Frame: Prior to and one month after booster vaccination. ]
  • Occurrence of Solicited local and general symptoms. [ Time Frame: During the 4-day (Day 0-3) follow-up period after booster vaccination. ]
  • Occurrence of Unsolicited adverse events. [ Time Frame: During the 31-day (Day 0-30) follow-up period after booster vaccination. ]
  • Occurrence of Serious adverse events. [ Time Frame: From the booster dose up to study end (Day 0 to Month 1). ]
Not Provided
Not Provided
 
Immunogenicity and Safety of GSK Biologicals' Boostrix Polio Vaccine in 3 and 4-year-old Children
Immunogenicity and Safety of GSK Biologicals' dTpa-IPV Vaccine (Boostrix Polio) as a Booster Dose in 3 and 4-year-old Children
The purpose of the study is to compare the immunogenicity and safety of a booster dose of BoostrixTM Polio to that of Sanofi Pasteur MSD's RepevaxTM, when co-administered with a second dose of PriorixTM, in healthy 3 and 4-year-old children.
Not Provided
Interventional
Phase 3
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: No masking
Primary Purpose: Prevention
  • Acellular Pertussis
  • Poliomyelitis
  • Tetanus
  • Diphtheria
  • Biological: Boostrix PolioTM
    Single dose, intramuscular administration.
  • Biological: RepevaxTM
    Single dose, intramuscular administration.
  • Biological: PriorixTM
    Single dose, intramuscular or subcutaneous administration.
  • Experimental: BOOSTRIX POLIO GROUP
    Healthy male or female children of 3 or 4 years of age, who were previously vaccinated with 3 doses of Infanrix™ and Polio™ vaccines in the German household contact study (APV-039), additionally received 1 booster dose of Boostrix™ Polio vaccine co-administered with Priorix™ vaccine at Day 0. Boostrix™ Polio vaccine was administered intramuscularly in the deltoid muscle of the left arm, while Priorix™ vaccine was administered subcutaneously in the deltoid region of the right arm or as an intramuscular injection into the deltoid muscle of the right arm.
    Interventions:
    • Biological: Boostrix PolioTM
    • Biological: PriorixTM
  • Active Comparator: REPEVAX GROUP
    Healthy male or female children of 3 or 4 years of age, who were previously vaccinated with 3 doses of Infanrix™ and Polio™ vaccines in the German household contact study (APV-039), additionally received 1 booster dose of Repevax™ vaccine co-administered with Priorix™ vaccine at Day 0. Repevax™ vaccine was administered intramuscularly in the deltoid muscle of the arm, while Priorix™ vaccine was administered subcutaneously in the deltoid region of the right arn or as an intramuscular injection into the deltoid muscle of the right arm.
    Interventions:
    • Biological: RepevaxTM
    • Biological: PriorixTM
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Completed
387
April 2, 2012
March 27, 2012   (Final data collection date for primary outcome measure)

Inclusion Criteria:

  • Subjects who the investigator believes that their parent(s)/Legally Acceptable Representative(s) (LAR) can and will comply with the requirements of the protocol should be enrolled in the study.
  • A male or female child of 3 or 4 years of age at the time of booster vaccination (up to, but excluding 5 years of age).
  • Subjects who have received a complete three-dose primary vaccination with diphtheria-tetanus-acellular pertussis (DTPa) vaccine and inactivated poliovirus (IPV) vaccine in the first six months of life, in line with recommendations in the United Kingdom (UK).
  • Subjects who received a first dose of a live attenuated measles-mumps-rubella vaccine within the second year of life, in line with recommendations in the UK.
  • Written informed consent obtained from the parent(s)/LAR(s) of the subject at the time of enrolment.
  • Healthy subjects as established by medical history and clinical examination before entering into the study.

Exclusion Criteria:

  • Child in care.
  • Use of any investigational or non-registered product other than the study vaccine(s) within 30 days preceding the booster dose of study vaccine, or planned use during the study period.
  • Chronic administration of immunosuppressants or other immune-modifying drugs within six months prior to the booster vaccine dose.
  • Administration of a vaccine not foreseen by the study protocol within 30 days prior to vaccination, or planned administration during the study period, with the exception of inactivated influenza vaccine.
  • Concurrently participating in another clinical study, at any time during the study period, in which the subject has been or will be exposed to an investigational or a non-investigational product.
  • Previous booster vaccination against diphtheria, tetanus, pertussis, poliomyelitis since primary vaccination in the first year of life.
  • Previous measles, mumps and/or rubella second dose vaccination.
  • Evidence of previous or intercurrent diphtheria, tetanus, pertussis, poliomyelitis, measles, mumps and/or rubella disease.
  • Known exposure to measles, mumps and/or rubella within 30 days prior to study start.
  • Any confirmed or suspected immunosuppressive or immunodeficiency condition, based on medical history and physical examination.
  • History of any reaction or hypersensitivity likely to be exacerbated by any component of the vaccine.
  • Administration of immunoglobulin and/or any blood products within the three months preceding the booster dose or planned administration during the study period.
  • Occurrence of transient thrombocytopenia or neurological complications following an earlier immunisation.
  • Occurrence of any of the following adverse events after a previous administration of a DTP vaccine:

    • Hypersensitivity reaction to any component of the vaccine;
    • Encephalopathy of unknown aetiology occurring within 7 days following previous vaccination with pertussis-containing vaccine;
    • Fever >= 40°C within 48 hours of vaccination, not due to another identifiable cause;
    • Collapse or shock-like state within 48 hours of vaccination;
    • Convulsions with or without fever, occurring within 3 days of vaccination.
  • Acute disease and/or fever at the time of enrolment or within 24 hours of study vaccine administration.
Sexes Eligible for Study: All
3 Years to 4 Years   (Child)
Yes
Contact information is only displayed when the study is recruiting subjects
United Kingdom
 
 
NCT01245049
111763
Not Provided
Not Provided
Not Provided
GlaxoSmithKline
GlaxoSmithKline
Not Provided
Study Director: GSK Clinical Trials GlaxoSmithKline
GlaxoSmithKline
February 2017

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP